In addition, the same authors [1] demonstrated that the αCT1 peptide was effective in modulating the junctional activity and distribution of Cx43 in breast cancer cells and highlighted the therapeutic potential of the αCT1 peptide in breast cancer treatment. The gene discussed is TRAF3IP2; the disease is breast carcinoma.